TSHR; | |
RECQL; GLA; TDP1; PKM; GLO1; ALOX12; HSD17B1; AKR1B1; HSD17B10; ALOX15; NOX4; USP2; TNKS; PARP1; TNKS2; CD38; POLB; | |
ACHE; | |
CFTR; | |
GSK3B; SYK; FLT3; CDK6; CSNK2A1; | |
CA2; CA12; CA7; CA4; | |
AR; | |
ESR2; ESR1; | |
ALOX5; MAOA; PTGS2; ALDH2; XDH; | |
KDM4E; | |
MMP9; MMP12; MMP2; | |
HIF1A; TP53; NFKB1; | |
ABCG2; ABCC1; | |
RAB9A; NPC1; LMNA; TTR; MAPT; THPO; APP; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.187E-11 | 6.521E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, XDH |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.071E-11 | 7.901E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, NOX4 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.832E-09 | 1.078E-06 | ABCG2, ACHE, APP, CD38, CSNK2A1, ESR1, ESR2, FLT3, GLA, MAPT, MMP9, NFKB1, PARP1, PKM, PTGS2, RAB9A, SMN1, SMN2, TP53, TTR, USP2, XDH |
MF | GO:0005488; binding | GO:0020037; heme binding | 6.542E-09 | 2.907E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, NOX4, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.557E-09 | 3.451E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.863E-08 | 6.340E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.487E-08 | 7.736E-06 | CA2, CA7, CD38, CDK6, CFTR, HIF1A, NPC1, PARP1, PTGS2, SYK, TNKS, TNKS2 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.583E-08 | 1.013E-05 | CA2, CA7, CFTR, HIF1A, NPC1, PTGS2, SYK, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.238E-08 | 1.183E-05 | ABCC1, ALOX12, ALOX15, ALOX5, SYK |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.197E-07 | 2.864E-05 | CA12, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.592E-07 | 3.688E-05 | ALOX12, ALOX15, ALOX5, PTGS2 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.748E-07 | 4.006E-05 | AR, CA12, CA2, CA4, CA7, ESR1, ESR2, GLO1, MMP12, MMP2, MMP9, PARP1, TNKS, TP53 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 2.513E-07 | 5.700E-05 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.625E-07 | 5.893E-05 | CA12, CA2, CA4, CA7, CFTR |
MF | GO:0005488; binding | GO:0005496; steroid binding | 2.978E-07 | 6.486E-05 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.174E-07 | 1.073E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.953E-07 | 1.178E-04 | CYP1A2, CYP2C19, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.149E-06 | 2.138E-04 | AKR1B1, ALDH2, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 3.540E-06 | 5.626E-04 | CA2, CA7, CFTR |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 4.856E-06 | 7.395E-04 | AR, CYP19A1, ESR1 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.915E-06 | 7.433E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 5.677E-06 | 8.410E-04 | AR, CA2, CD38, FLT3, NPC1, PARP1, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.460E-06 | 9.378E-04 | CYP1A2, CYP2C19, CYP3A4 |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 9.506E-06 | 1.302E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 9.810E-06 | 1.303E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 9.810E-06 | 1.303E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 9.810E-06 | 1.303E-03 | ALOX12, ALOX15 |
BP | GO:0050896; response to stimulus | GO:0032870; cellular response to hormone stimulus | 1.182E-05 | 1.532E-03 | AR, ESR1, FLT3, NFKB1, NPC1, PARP1, PKM, TSHR |
BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 1.203E-05 | 1.541E-03 | AKR1B1, ALDH2, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0050896; response to stimulus | GO:1901654; response to ketone | 2.053E-05 | 2.460E-03 | AKR1B1, AR, CD38, CFTR, CSNK2A1, PARP1 |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 2.529E-05 | 2.961E-03 | NOX4, PARP1, POLB, TP53 |
MF | GO:0005488; binding | GO:0019899; enzyme binding | 2.641E-05 | 3.043E-03 | APP, AR, CFTR, CYP1A1, CYP1A2, CYP2C19, CYP3A4, ESR1, ESR2, GSK3B, HIF1A, MAPT, PARP1, POLB, PTGS2, SYK, TNKS2, TP53, USP2 |
BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 2.918E-05 | 3.214E-03 | AKR1B1, CDK6, CFTR, CYP1B1, NFKB1, PTGS2, TP53 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.937E-05 | 3.214E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 2.937E-05 | 3.214E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.937E-05 | 3.214E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.937E-05 | 3.214E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.937E-05 | 3.214E-03 | ALOX12, ALOX15 |
BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 3.327E-05 | 3.523E-03 | APP, CDK6, GSK3B, HIF1A, MAPT, PARP1, PTGS2, SYK, TP53, XDH |
BP | GO:0040007; growth | GO:0040008; regulation of growth | 3.505E-05 | 3.669E-03 | ALOX12, APP, AR, CD38, CSNK2A1, ESR2, HIF1A, MAPT, TNKS2, TP53 |
BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 3.589E-05 | 3.730E-03 | APP, AR, CD38, CSNK2A1, ESR1, ESR2, GLA, GSK3B, HIF1A, MAPT, MMP12, MMP9, NFKB1, NPC1, PARP1, PTGS2, TNKS, TNKS2, TP53, USP2, XDH |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.827E-05 | 3.950E-03 | CYP1A1, POLB, TP53 |
BP | GO:0050896; response to stimulus | GO:0048585; negative regulation of response to stimulus | 4.510E-05 | 4.568E-03 | ALOX12, ALOX15, AR, CDK6, CYP19A1, ESR1, ESR2, GSK3B, HIF1A, LMNA, MMP12, MMP9, NFKB1, PTGS2, XDH |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.073E-05 | 5.022E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 5.192E-05 | 5.098E-03 | APP, HIF1A, NOX4, PARP1, POLB, PTGS2, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 5.221E-05 | 5.098E-03 | APP, CFTR, CYP19A1, CYP1B1, NPC1 |
BP | GO:0065007; biological regulation | GO:0050790; regulation of catalytic activity | 5.400E-05 | 5.249E-03 | APP, AR, CSNK2A1, ESR1, FLT3, GLA, GSK3B, HIF1A, MAPT, MMP9, NFKB1, NOX4, PARP1, PTGS2, SYK, TNKS, TP53, TSHR, XDH |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 5.862E-05 | 5.478E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.862E-05 | 5.478E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 5.862E-05 | 5.478E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.862E-05 | 5.478E-03 | CYP1A2, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 5.944E-05 | 5.531E-03 | APP, CSNK2A1, CYP1B1, ESR1, GLA, GSK3B, MAPT, MMP9, NFKB1, PTGS2, RAB9A, TNKS, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0051240; positive regulation of multicellular organismal process | 6.492E-05 | 5.964E-03 | ALOX12, APP, AR, CA2, CD38, CYP1B1, HIF1A, MAPT, MMP12, MMP9, NFKB1, PARP1, PTGS2, SYK, THPO |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.398E-05 | 6.657E-03 | CYP19A1, CYP1A2, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 7.398E-05 | 6.657E-03 | PARP1, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 7.521E-05 | 6.740E-03 | ACHE, ALDH2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, GLA, GSK3B, HSD17B10, MAOA, PKM, TP53, USP2, XDH |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 7.602E-05 | 6.784E-03 | ALOX15, ESR1, GSK3B, MAPT, PARP1, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 8.304E-05 | 7.262E-03 | CYP1B1, HIF1A, PTGS2 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 8.304E-05 | 7.262E-03 | PARP1, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 8.304E-05 | 7.262E-03 | APP, GSK3B, PARP1 |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 9.280E-05 | 8.019E-03 | CYP19A1, CYP3A4, ESR1 |
BP | GO:0008152; metabolic process | GO:0031328; positive regulation of cellular biosynthetic process | 9.474E-05 | 8.135E-03 | APP, AR, CD38, ESR1, ESR2, HIF1A, MMP12, NFKB1, NOX4, PARP1, PTGS2, SYK, TNKS, TNKS2, TP53, TSHR |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 9.659E-05 | 8.135E-03 | ACHE, CD38, CFTR, HIF1A, MMP12, SYK |
BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 9.743E-05 | 8.135E-03 | AKR1B1, MMP2, MMP9, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 9.748E-05 | 8.135E-03 | APP, CFTR, NOX4, PTGS2, TP53 |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 9.750E-05 | 8.135E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 9.750E-05 | 8.135E-03 | CYP1A1, CYP3A4 |
BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.025E-04 | 8.488E-03 | GSK3B, MAPT, PARP1, TP53 |
BP | GO:0008152; metabolic process | GO:0072330; monocarboxylic acid biosynthetic process | 1.039E-04 | 8.541E-03 | ALOX12, ALOX15, CYP1A1, PKM, PTGS2 |
BP | GO:0008152; metabolic process | GO:0051186; cofactor metabolic process | 1.166E-04 | 9.303E-03 | ABCC1, AKR1B1, CD38, CYP1A1, CYP1A2, GLO1, PKM, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 1.236E-04 | 9.786E-03 | ALOX15, CD38, FLT3, GSK3B, HIF1A, NFKB1, PTGS2, TP53 |
BP | GO:0008152; metabolic process | GO:0032963; collagen metabolic process | 1.249E-04 | 9.851E-03 | HIF1A, MMP12, MMP2, MMP9 |
BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 1.263E-04 | 9.932E-03 | AR, CDK6, CFTR, ESR1, FLT3, NFKB1, NPC1 |
BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 1.270E-04 | 9.945E-03 | ALOX15, GSK3B, HIF1A, MAPT, MMP9, NOX4, TNKS, TNKS2, TP53 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.954E-09 | 1.477E-06 | HSD17B1; ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.040E-07 | 4.288E-06 | MAOA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PKM; ALDH2; HSD17B1; ALOX5; CYP1A2; CYP1A1; CD38; XDH |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.859E-08 | 2.672E-06 | APP; MAOA; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.238E-08 | 1.846E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.104E-07 | 6.401E-06 | AR; GSK3B; CDK6; FLT3; MMP2; PTGS2; HIF1A; TP53; MMP9; NFKB1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.353E-07 | 4.312E-06 | ALDH2; MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.830E-07 | 4.312E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.264E-06 | 2.318E-05 | ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 3.615E-06 | 5.422E-05 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; NFKB1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 9.446E-06 | 1.299E-04 | SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.260E-05 | 4.062E-04 | ABCC1; CDK6; CYP1B1; PTGS2; TP53; MMP9; NFKB1 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.447E-05 | 4.062E-04 | GSK3B; SYK; CSNK2A1; CD38; TP53; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.743E-05 | 4.117E-04 | POLB; CDK6; PKM; SYK; TP53; NFKB1 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.809E-07 | 4.312E-06 | CA12; CA2; CA4; CA7 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.757E-06 | 2.898E-05 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.199E-05 | 5.361E-04 | PKM; FLT3; TP53; HIF1A |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 6.899E-05 | 5.991E-04 | GSK3B; ESR1; NFKB1; ESR2 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.837E-05 | 5.665E-04 | MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.575E-04 | 1.130E-03 | GSK3B; AR; TP53; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.531E-05 | 5.987E-04 | CA2; CYP3A4; CFTR; ABCG2 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.283E-05 | 6.008E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.379E-04 | 1.035E-03 | CDK6; PTGS2; TP53; NFKB1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.374E-04 | 1.624E-03 | MMP2; ESR1; MMP9; ESR2 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.846E-04 | 2.267E-03 | MMP2; TP53; HIF1A; ESR1; MMP9 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.636E-04 | 2.638E-03 | GSK3B; TP53; ESR1; HIF1A |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.810E-04 | 4.689E-03 | PARP1; LMNA; TP53; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.030E-03 | 5.154E-03 | CDK6; TP53; MMP9; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.727E-03 | 7.702E-03 | APP; GSK3B; MAPT; HSD17B10 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.442E-03 | 6.611E-03 | GSK3B; SYK; NFKB1 |
hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 7.772E-04 | 4.274E-03 | ALDH2; AKR1B1; GLA |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.077E-03 | 5.229E-03 | CDK6; TP53; NFKB1 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.220E-03 | 9.399E-03 | FLT3; TP53; MMP9; NFKB1 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.812E-03 | 1.430E-02 | GSK3B; CDK6; SYK; TP53; NFKB1 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.650E-04 | 1.682E-03 | MMP2; MMP9; TP53 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.442E-03 | 6.611E-03 | CDK6; TP53; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.031E-03 | 5.154E-03 | CYP1A2; CYP1A1; CYP3A4 |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 2.461E-04 | 1.624E-03 | PKM; ALDH2; GLO1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.622E-03 | 1.658E-02 | PTGS2; MMP9; NFKB1 |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 2.464E-03 | 9.916E-03 | THPO; FLT3; CD38 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.271E-04 | 1.999E-03 | ABCC1; CFTR; ABCG2 |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 3.153E-03 | 1.239E-02 | CA2; CD38; CFTR |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.886E-03 | 1.982E-02 | GSK3B; TP53; NFKB1 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 7.942E-03 | 2.520E-02 | POLB; GSK3B; TP53; NFKB1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.886E-03 | 1.982E-02 | ABCC1; TP53; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 7.812E-03 | 2.520E-02 | GSK3B; TP53; NFKB1 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 6.444E-03 | 2.127E-02 | GSK3B; CDK6; TP53 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 9.340E-03 | 2.830E-02 | GSK3B; CSNK2A1; TP53 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.893E-02 | 4.662E-02 | CSNK2A1; TP53; NFKB1 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.987E-02 | 4.821E-02 | CDK6; TP53 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.683E-02 | 4.338E-02 | CDK6; TP53 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.268E-02 | 3.429E-02 | PTGS2; TSHR |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.539E-02 | 4.030E-02 | GSK3B; TP53 |
hsa00010 | Glycolysis / Gluconeogenesis_Homo sapiens_hsa00010 | 1.782E-02 | 4.523E-02 | PKM; ALDH2 |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.883E-02 | 4.662E-02 | CDK6; TP53 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.100E-02 | 3.130E-02 | GSK3B; TP53 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.268E-02 | 3.429E-02 | CDK6; TP53 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.311E-02 | 3.490E-02 | FLT3; NFKB1 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.225E-02 | 3.426E-02 | GSK3B; TP53 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 9.814E-03 | 2.892E-02 | MAOA; NFKB1 |
hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 1.020E-02 | 2.954E-02 | ALDH2; MAOA |
hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 9.432E-03 | 2.830E-02 | ALDH2; HSD17B10 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 8.688E-03 | 2.705E-02 | CYP3A4; XDH |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.768E-03 | 1.430E-02 | AKR1B1; GLA |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 5.393E-03 | 1.893E-02 | ALDH2; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.546E-03 | 1.658E-02 | POLB; PARP1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.221E-03 | 9.399E-03 | CA2; CA4 |
hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 2.419E-03 | 9.916E-03 | ALDH2; MAOA |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.097E-05 | 7.147E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
NA: NA | Male hypogonadism | NA | AR |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; SYK; AKR1B1; PTGS2; PTGS2; PTGS2; PTGS2 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2; PTGS2 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ALDH2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
NA: NA | Joint and muscular pain | NA | PTGS2 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; MMP12; PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
C00-D49: Neoplasms | Ovarian cancer | C56 | PARP1; MMP2 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53; CD38 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | CLL | NA | FLT3 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1; ALDH2 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; AKR1B1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; SYK; HIF1A; TP53; FLT3; FLT3; MMP9; NFKB1; ACHE; ESR1; ESR1; PARP1; MMP2; PTGS2; CD38; APP; CSNK2A1 |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
C00-D49: Neoplasms | AML | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | APP |
NA: NA | Geographic retinal atrophy | NA | APP |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1 |
NA: NA | GIST | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PTGS2; ABCC1; ABCC1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; MMP2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2; ABCC1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; MMP12; PTGS2 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PTGS2 |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | SYK; HIF1A; TP53; FLT3; MMP9; MMP2; PKM |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; MAOA; PTGS2; MAPT; APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
C00-D49: Neoplasms | Melanoma | C43 | PARP1 |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |